JP4838722B2 - ポリヌクレオチドを送達する方法、及び送達用組成物 - Google Patents

ポリヌクレオチドを送達する方法、及び送達用組成物 Download PDF

Info

Publication number
JP4838722B2
JP4838722B2 JP2006536845A JP2006536845A JP4838722B2 JP 4838722 B2 JP4838722 B2 JP 4838722B2 JP 2006536845 A JP2006536845 A JP 2006536845A JP 2006536845 A JP2006536845 A JP 2006536845A JP 4838722 B2 JP4838722 B2 JP 4838722B2
Authority
JP
Japan
Prior art keywords
polynucleotide
protein
mitochondrial
recombinant polypeptide
membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006536845A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007508846A (ja
JP2007508846A5 (enExample
Inventor
クハン シャハルヤル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gencia Corp
Original Assignee
Gencia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gencia Corp filed Critical Gencia Corp
Publication of JP2007508846A publication Critical patent/JP2007508846A/ja
Publication of JP2007508846A5 publication Critical patent/JP2007508846A5/ja
Application granted granted Critical
Publication of JP4838722B2 publication Critical patent/JP4838722B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/07—Fusion polypeptide containing a localisation/targetting motif containing a mitochondrial localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
JP2006536845A 2003-10-24 2004-10-25 ポリヌクレオチドを送達する方法、及び送達用組成物 Expired - Fee Related JP4838722B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US51398303P 2003-10-24 2003-10-24
US60/513,983 2003-10-24
US56843604P 2004-05-05 2004-05-05
US60/568,436 2004-05-05
PCT/US2004/035137 WO2005056752A2 (en) 2003-10-24 2004-10-25 Methods and compositions for delivering polynucleotides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011003814A Division JP2011137001A (ja) 2003-10-24 2011-01-12 ポリヌクレオチドを送達する方法、及び送達用組成物

Publications (3)

Publication Number Publication Date
JP2007508846A JP2007508846A (ja) 2007-04-12
JP2007508846A5 JP2007508846A5 (enExample) 2010-04-22
JP4838722B2 true JP4838722B2 (ja) 2011-12-14

Family

ID=34681406

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006536845A Expired - Fee Related JP4838722B2 (ja) 2003-10-24 2004-10-25 ポリヌクレオチドを送達する方法、及び送達用組成物
JP2011003814A Pending JP2011137001A (ja) 2003-10-24 2011-01-12 ポリヌクレオチドを送達する方法、及び送達用組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011003814A Pending JP2011137001A (ja) 2003-10-24 2011-01-12 ポリヌクレオチドを送達する方法、及び送達用組成物

Country Status (7)

Country Link
US (2) US8039587B2 (enExample)
EP (2) EP1687017B1 (enExample)
JP (2) JP4838722B2 (enExample)
AU (2) AU2004297533B2 (enExample)
CA (1) CA2543257C (enExample)
ES (1) ES2411962T3 (enExample)
WO (1) WO2005056752A2 (enExample)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070196334A1 (en) * 2003-06-25 2007-08-23 Shaharyar Khan Modified vectors for organelle transfection
US20090123468A1 (en) * 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
CA2543257C (en) 2003-10-24 2013-12-31 Gencia Corporation Methods and compositions for delivering polynucleotides
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
CA2564616C (en) * 2004-04-20 2016-08-30 Nastech Pharmaceutical Company Inc. Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells
US20060035815A1 (en) * 2004-05-04 2006-02-16 Nastech Pharmaceutical Company Inc. Pharmaceutical compositions for delivery of ribonucleic acid to a cell
US20060040882A1 (en) * 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
CA2621694A1 (en) * 2005-09-08 2007-03-15 Nastech Pharmaceutical Company Inc. Pharmaceutical compositions for delivery of ribonucleic acid to a cell
AU2006304291A1 (en) * 2005-10-14 2007-04-26 Marina Biotech, Inc. Compounds and methods for peptide ribonucleic acid condensate particles for RNA therapeutics
US8273867B2 (en) * 2006-02-10 2012-09-25 The Regents Of The University Of California Transducible delivery of siRNA by dsRNA binding domain fusions to PTD/CPPS
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
PL2450437T3 (pl) 2006-04-14 2017-12-29 Cell Signaling Technology Inc Defekty genu i zmutowana kinaza ALK w ludzkich guzach litych
US20070281900A1 (en) * 2006-05-05 2007-12-06 Nastech Pharmaceutical Company Inc. COMPOSITIONS AND METHODS FOR LIPID AND POLYPEPTIDE BASED siRNA INTRACELLULAR DELIVERY
US20070275923A1 (en) * 2006-05-25 2007-11-29 Nastech Pharmaceutical Company Inc. CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY
EP2046964B1 (en) * 2006-07-12 2018-07-04 The Regents of The University of California Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups
WO2008038766A1 (en) * 2006-09-29 2008-04-03 National University Corporation Gunma University Functional peptide having activity of stimulating immune cell
EP2121914B1 (en) * 2007-02-16 2014-08-20 John Guy Mitochondrial nucleic acid delivery systems
CN101466721B (zh) * 2007-04-13 2013-08-21 细胞信号技术公司 在人实体瘤中的基因缺损和突变体alk激酶
US9061076B2 (en) 2007-05-25 2015-06-23 North Carolina State University Viral nanoparticle cell-targeted delivery platform
EP2195001A4 (en) * 2007-08-29 2012-10-24 Univ Tufts METHODS OF MAKING AND USING CELL PENETRATING PEPTIDE TO ENHANCE ADMINISTRATION OF NUCLEIC ACIDS, PROTEINS, MEDICINES, AND ADENOVIRUS TO TISSUES AND CELLS, AND COMPOSITIONS AND KITS
ATE530647T1 (de) * 2007-12-12 2011-11-15 Mitogenomix Gmbh Verfahren zur erzeugung von rhoo-zellen
US9260493B2 (en) 2009-05-07 2016-02-16 The Regents Of The University Of California Transducible delivery of nucleic acids using modified dsRNA binding domains
CN102869384B (zh) 2009-06-22 2016-01-13 伯纳姆医学研究所 使用带有c-端元件的肽和蛋白质的方法和组合物
CN103037840A (zh) * 2010-04-21 2013-04-10 国立大学法人北海道大学 具有核内转运性的脂质膜结构体
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
WO2012051306A2 (en) 2010-10-12 2012-04-19 Gencia Corporation Compositions and methods for modulating mitochondrial proteases
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
EP2715291A4 (en) 2011-05-31 2015-10-21 Airware Inc NON-DISPERSIVE GAS SENSORS WITH ABSORPTION INFRARED ABSORPTION (NDIR)
RU2593956C2 (ru) * 2011-08-04 2016-08-10 Министерство Сельского Хозяйства И Сельскохозяйственной Продукции Ее Величества Королевы Канады По Праву Органоидно-направленные наноносители
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
WO2013043580A2 (en) 2011-09-19 2013-03-28 Gencia Corporation Modified creatine compounds
WO2013103972A1 (en) 2012-01-06 2013-07-11 Gencia Corporation Treatment of frailty syndrome and symptoms thereof
WO2013142167A1 (en) * 2012-03-20 2013-09-26 The University Of Iowa Research Foundation Gb virus c (hepatitis g virus) e2 glycoprotein as an immunomodulatory agent
US20160038565A1 (en) * 2012-06-15 2016-02-11 Gencia Corporation Methods of Mitigating Side Effects of Radiation Exposure and Chemotherapy
WO2013188873A1 (en) 2012-06-15 2013-12-19 Gencia Corporation Compositions and methods for enhancing immune responses
WO2014031575A1 (en) 2012-08-20 2014-02-27 The Regents Of The University Of California Polynucleotides having bioreversible groups
WO2014077195A1 (ja) 2012-11-19 2014-05-22 独立行政法人科学技術振興機構 人工生体粒子およびその製造方法
WO2014144017A2 (en) 2013-03-15 2014-09-18 Gencia Corporation Compositions and methods for treating conditions that affect epidermis
WO2014144442A2 (en) 2013-03-15 2014-09-18 Techulon Inc. Antisense molecules for treatment of staphylococcus aureus infection
KR20160021076A (ko) 2013-03-15 2016-02-24 테출론 인코포레이티드 스타필로코커스 아우레우스 감염의 치료를 위한 안티센스 분자
US10287331B2 (en) * 2013-04-15 2019-05-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Mitochondrial proteins constructs and uses thereof
WO2015006641A2 (en) 2013-07-12 2015-01-15 Georgia State University Research Foundation, Inc. Methods and compositions for interference with dna polymerase and dna synthesis
WO2015044704A1 (en) * 2013-09-30 2015-04-02 Sanofi Use of neuroglobin agonist for preventing or treating mitochondrial rcci and/or rcciii deficiency disease
CN104630149B (zh) * 2013-11-08 2018-08-21 中国科学院广州生物医药与健康研究院 外源线粒体导入到哺乳动物细胞中的方法
JP6744225B2 (ja) * 2014-02-14 2020-08-19 シンヴィヴォ コーポレイション ハイブリッドタンパクおよびその使用
EP3291829A1 (en) * 2015-05-03 2018-03-14 The Regents of the University of Colorado, a body corporate Propionyl-coa carboxylase compositions and uses thereof
CN104945491A (zh) * 2015-07-01 2015-09-30 扬州大学 一个叶绿体发育必需的蛋白质及其基因和应用
WO2017173453A1 (en) 2016-04-01 2017-10-05 The Brigham And Women's Hospital, Inc. Stimuli-responsive nanoparticles for biomedical applications
WO2017221271A1 (en) * 2016-06-22 2017-12-28 Indian Institute Of Technology Delhi Organelle-targeting nanocarrier
WO2018035380A1 (en) 2016-08-17 2018-02-22 Solstice Biologics, Ltd. Polynucleotide constructs
WO2018096457A1 (en) * 2016-11-22 2018-05-31 Kabushiki Kaisha Toshiba Nucleic acid condensing peptide, nucleic acid condensing peptide set, nucleic acid delivery carrier, nucleic acid delivery method, cell production method, cell detection method and kit
WO2018112470A1 (en) 2016-12-16 2018-06-21 The Brigham And Women's Hospital, Inc. Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
US11981752B2 (en) 2017-05-02 2024-05-14 Sanford Burnham Prebys Medical Discovery Institute Tumor associated monocyte/macrophage binding peptide and methods of use thereof
WO2018227112A1 (en) 2017-06-09 2018-12-13 The Trustees Of Columbia University In The City Of New York Short tat oligomers for drug delivery
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
US20210310002A1 (en) * 2018-08-31 2021-10-07 City Of Hope Cationic compounds for delivery of nucleic acids
WO2020118115A1 (en) * 2018-12-06 2020-06-11 Arcturus Therapeutics, Inc. Compositions and methods for treating ornithine transcarbamylase deficiency
WO2020161602A1 (en) 2019-02-04 2020-08-13 University Of Tartu Bi-specific extracellular matrix binding peptides and methods of use thereof
US11789029B2 (en) * 2019-06-21 2023-10-17 Arizona Board Of Regents On Behalf Of Arizona State University Temporal traumatic brain injury biomarkers and methods of use thereof
JP7745544B2 (ja) 2019-10-24 2025-09-29 イメル バイオセラピューティクス，インク． ミトコンドリアｄｎａ中のマクロヘテロプラスミー及びミクロヘテロプラスミーを検出するための方法
CN111034736B (zh) * 2019-12-13 2021-04-06 西北农林科技大学 一种杀虫组合物及其应用
EP4114470A4 (en) 2020-03-03 2024-04-17 Arcturus Therapeutics, Inc. Compositions and methods for the treatment of ornithine transcarbamylase deficiency
JP2020156481A (ja) * 2020-04-06 2020-10-01 セル・シグナリング・テクノロジー・インコーポレイテツド ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ
CN113832111A (zh) * 2020-06-23 2021-12-24 南京大学 一种类外泌体技术用于制备新型溶瘤病毒的方法
EP4408457A1 (en) 2021-09-30 2024-08-07 Yale University Compositions and methods for the treatment of autosomal dominant polycystic kidney disease and other diseases having upregulated mtor activity
US20250297233A1 (en) * 2022-04-26 2025-09-25 The General Hospital Corporation Genetically encoded systems for generating oxygen in living eukaryotic cells
WO2024042466A1 (en) 2022-08-22 2024-02-29 University Of Tartu Brain penetrating peptides and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058488A2 (en) * 1999-03-31 2000-10-05 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides

Family Cites Families (249)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US580445A (en) * 1897-04-13 Motor-engine
US5693489A (en) 1984-03-30 1997-12-02 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4622302A (en) 1984-08-09 1986-11-11 American National Red Cross Process for inducing membrane fusion under an electric field
US4752473A (en) 1984-10-12 1988-06-21 The Regents Of The University Of California Expression of glycosylated human influenza hemagglutinin proteins
US4873089A (en) 1985-07-12 1989-10-10 Cornell Research Foundation Inc., Cornell University Proteoliposomes as drug carriers
EP0257362A1 (de) 1986-08-27 1988-03-02 Siemens Aktiengesellschaft Addierer
US4803072A (en) 1986-09-10 1989-02-07 Smithkline Beckman Corporation Immunomodulation
US5149782A (en) 1988-08-19 1992-09-22 Tanox Biosystems, Inc. Molecular conjugates containing cell membrane-blending agents
US6306625B1 (en) 1988-12-30 2001-10-23 Smithkline Beecham Biologicals, Sa Method for obtaining expression of mixed polypeptide particles in yeast
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
JPH04222599A (ja) 1990-04-20 1992-08-12 Syntex Usa Inc 二重受容体ポリヌクレオチド検定方法
US5709879A (en) 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
US5985318A (en) 1990-08-24 1999-11-16 Burroughs Wellcome Co. Fusogenic liposomes that are free of active neuraminidase
US5166898A (en) 1990-09-07 1992-11-24 Nec Corporation Shift amount floating-point calculating circuit with a small amount of hardware and rapidly operable
US5756041A (en) 1991-07-11 1998-05-26 Arruda; William C. Method and apparatus for processing blown tube films
US5981273A (en) 1991-09-30 1999-11-09 Boehringer Ingelheim Int'l. Gmbh Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5780444A (en) 1991-12-13 1998-07-14 Trustees Of Princeton University Compositions and methods for cell transformation
US5422277A (en) 1992-03-27 1995-06-06 Ortho Diagnostic Systems Inc. Cell fixative composition and method of staining cells without destroying the cell surface
US6113946A (en) 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
US6080791A (en) 1992-07-24 2000-06-27 Seres Laboratories, Inc. Method of treating a viral condition by inhibiting membrane fusion
US6337070B1 (en) 1993-04-29 2002-01-08 Takara Shuzo Co., Ltd. Polypeptides for use in generating anti-human influenza virus antibodies
AU689755B2 (en) 1992-09-22 1998-04-09 Biofocus Discovery Limited Recombinant viruses displaying a nonviral polypeptide on their external surface
US5552155A (en) 1992-12-04 1996-09-03 The Liposome Company, Inc. Fusogenic lipsomes and methods for making and using same
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US20030022315A1 (en) 1993-06-14 2003-01-30 Basf Aktiengesellschaft And Knoll Aktiengesellschaft Tetracycline-inducible transcriptional inhibitor fusion proteins
US5589362A (en) 1993-06-14 1996-12-31 Basf Aktiengesellschaft Tetracycline regulated transcriptional modulators with altered DNA binding specificities
US5859310A (en) 1993-06-14 1999-01-12 Basf Aktiengesellschaft Mice transgenic for a tetracycline-controlled transcriptional activator
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5654168A (en) 1994-07-01 1997-08-05 Basf Aktiengesellschaft Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units
US5912411A (en) 1993-06-14 1999-06-15 University Of Heidelberg Mice transgenic for a tetracycline-inducible transcriptional activator
US6004941A (en) 1993-06-14 1999-12-21 Basf Aktiengesellschaft Methods for regulating gene expression
US5888981A (en) 1993-06-14 1999-03-30 Basf Aktiengesellschaft Methods for regulating gene expression
AU684524B2 (en) 1993-06-14 1997-12-18 Tet Systems Holding Gmbh & Co. Kg Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5866755A (en) 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
US5789156A (en) 1993-06-14 1998-08-04 Basf Ag Tetracycline-regulated transcriptional inhibitors
GB9317380D0 (en) 1993-08-20 1993-10-06 Therexsys Ltd Transfection process
DE4335025A1 (de) 1993-10-14 1995-04-20 Boehringer Ingelheim Int Endosomolytisch wirksame Partikel
WO1995031183A1 (en) 1994-05-16 1995-11-23 Washington University Cell membrane fusion composition and method
US5728399A (en) 1994-06-29 1998-03-17 University Of Conn. Use of a bacterial component to enhance targeted delivery of polynucleotides to cells
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US5799515A (en) 1995-02-17 1998-09-01 Floyd; Herbert R. Auto column pivot lock
US5733540A (en) 1995-03-08 1998-03-31 Lee; Peter Poon-Hang Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria
US5723319A (en) 1995-06-05 1998-03-03 Avid Therapeutics, Inc. Cultured cell line that inducibly expresses the hepatitis B virus genome, and uses thereof for screening antiviral substances
US5851796A (en) 1995-06-07 1998-12-22 Yale University Autoregulatory tetracycline-regulated system for inducible gene expression in eucaryotes
US5908777A (en) 1995-06-23 1999-06-01 University Of Pittsburgh Lipidic vector for nucleic acid delivery
US6017734A (en) 1995-07-07 2000-01-25 The Texas A & M University System Unique nucleotide and amino acid sequence and uses thereof
GB9515356D0 (en) 1995-07-26 1995-09-20 Medical Res Council Improvements in or relating to delivery of nucleic acid
DE69632303T2 (de) 1995-08-17 2005-05-12 Crucell Holland B.V. Poly(organo)phosphazene in synthetischen transfektions-systemen
AU7342296A (en) 1995-10-25 1997-05-15 Octoplus Bv Cationic polyacrylates and poly(alkyl) acrylates or the corresponding acrylamides for use in synthetic transfection or blocking systems
US5804445A (en) 1996-01-11 1998-09-08 Board Of Regents, The University Of Texas System High affinity mutants of nuclear factor-interleukin 6 and methods of use therefor
RU2201961C2 (ru) 1996-01-29 2003-04-10 Кие-Хиунг ПАЙК Способ получения белка с использованием трансляционной системы митохондрий
US6037348A (en) 1996-02-09 2000-03-14 Eli Lilly And Company Inhibition of viral replication
RU2066552C1 (ru) 1996-02-12 1996-09-20 Товарищество с ограниченной ответственностью "Био Прогресс" Композиция для фотодинамического повреждения клеток-мишеней и способ фотодинамического повреждения клеток-мишеней
DE19605279A1 (de) 1996-02-13 1997-08-14 Hoechst Ag Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung
US5770414A (en) 1996-02-20 1998-06-23 The Regents Of The University Of California Regulatable retrovirus system for genetic modification of cells
JP2000509404A (ja) 1996-05-08 2000-07-25 ニカ ヘルス プロダクツ リミテッド 遺伝物質の導入システムとしてのカチオン性ヴィロソーム
US6004808A (en) 1996-06-21 1999-12-21 Aurora Biosciences Corporation Promiscuous G-protein compositions and their use
US5948681A (en) 1996-08-14 1999-09-07 Children's Hospital Of Philadelphia Non-viral vehicles for use in gene transfer
US6255071B1 (en) 1996-09-20 2001-07-03 Cold Spring Harbor Laboratory Mammalian viral vectors and their uses
US6025192A (en) 1996-09-20 2000-02-15 Cold Spring Harbor Laboratory Modified retroviral vectors
US5854016A (en) 1996-09-27 1998-12-29 Icos Corporation Creba Isoform
IL130822A (en) 1996-10-15 2005-12-18 Elan Pharm Inc N-acyl phosphatidylethanolamine-mediated liposomaldrug delivery
US20020155095A1 (en) 1996-10-18 2002-10-24 Tattanahalli L. Nagabhushan Methods and compositions for delivery and expression of interferon-a nucleic acids
GB9623051D0 (en) 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
FR2759382A1 (fr) 1997-02-10 1998-08-14 Transgene Sa Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
DE19716732C2 (de) 1997-03-07 1999-03-25 Max Delbrueck Centrum Spezifische Magnetosomen, Verfahren zu ihrer Herstellung und ihre Verwendung
US5831020A (en) 1997-03-25 1998-11-03 The Research Foundation Of State University Of New York Protein-mediated nuclear import of DNA
US6368821B1 (en) 1997-04-14 2002-04-09 Stratagene Process for infecting eukaryotic cells with a bacterial virus
US6099847A (en) 1997-05-15 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric Gag pseudovirions
GB9711115D0 (en) 1997-05-29 1997-07-23 Inst Of Child Health Integrin-targeting vectors having enhanced transfection activity
US6127159A (en) * 1997-06-06 2000-10-03 The Board Of Trustees Of The Leland Stanford Junior University Mitofusin genes and their uses
US6635623B1 (en) * 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
US7811803B2 (en) 1997-06-19 2010-10-12 University Of Medicine And Dentistry Of New Jersey Methods and compositions for rapid purification of proteasomes and methods of use of components thereof
WO1998057978A1 (en) 1997-06-19 1998-12-23 University Of Medicine And Dentistry Of New Jersey Methods and compositions for rapid purification of proteasomes and methods of use of components thereof
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
US6087166A (en) 1997-07-03 2000-07-11 Basf Aktiengesellschaft Transcriptional activators with graded transactivation potential
FR2766195A1 (fr) 1997-07-21 1999-01-22 Transgene Sa Polymeres cationiques, complexes associant lesdits polymeres cationiques et des substances therapeutiquement actives comprenant au moins une charges negative, notamment des acides nucleiques, et leur utilisation en therapie genique
US6207648B1 (en) 1997-07-24 2001-03-27 Trustees Of Boston University Methods of using cytochrome P450 reductase for the enhancement of P450-based anti-cancer gene therapy
US6054312A (en) 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
WO1999013905A1 (en) 1997-09-18 1999-03-25 The Trustees Of The University Of Pennsylvania Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery
GB9720148D0 (en) 1997-09-22 1997-11-26 Innes John Centre Innov Ltd Gene silencing materials and methods
US6734171B1 (en) 1997-10-10 2004-05-11 Inex Pharmaceuticals Corp. Methods for encapsulating nucleic acids in lipid bilayers
US6136536A (en) 1997-10-29 2000-10-24 Genetics Institute, Inc. Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
US5968773A (en) 1997-11-14 1999-10-19 Heddle; John A. System and method for regulation of gene expression
IT1297090B1 (it) 1997-12-01 1999-08-03 Barbara Ensoli Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le
US6221355B1 (en) * 1997-12-10 2001-04-24 Washington University Anti-pathogen system and methods of use thereof
AU740342B2 (en) 1997-12-12 2001-11-01 Samyang Corporation Biodegradable mixed polymeric micelles for gene delivery
US6410057B1 (en) 1997-12-12 2002-06-25 Samyang Corporation Biodegradable mixed polymeric micelles for drug delivery
AR014940A1 (es) 1997-12-12 2001-04-11 Expression Genetics Inc Un portador para la liberacion de un agente bioactivo, un polimero poliester biodegradable, copolimeros y composiciones farmaceuticas que loscontienen.
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6372720B1 (en) 1998-02-05 2002-04-16 Kenneth J. Longmuir Liposome fusion and delivery vehicle
WO1999042091A2 (en) 1998-02-19 1999-08-26 Massachusetts Institute Of Technology Use of polycations as endosomolytic agents
US6737506B1 (en) 1998-02-25 2004-05-18 Paul Anziano Manganese superoxide dismutase exon 3-deleted isoforms and nucleic acid molecules encoding the isoforms
HUP9900956A2 (hu) 1998-04-09 2002-04-29 Aventis Pharma Deutschland Gmbh. Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk
US6986902B1 (en) 1998-04-28 2006-01-17 Inex Pharmaceuticals Corporation Polyanionic polymers which enhance fusogenicity
WO1999064581A1 (en) 1998-06-10 1999-12-16 University Of South Florida Electrofusion chamber
US6143564A (en) 1998-07-07 2000-11-07 University Of Hawaii Use of the polar body chromosomes for the production of embryos and normal offspring
US6759236B1 (en) 1998-08-18 2004-07-06 Research Development Foundation Methods to enhance and confine expression of genes
US20040071736A1 (en) 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
AU5779499A (en) 1998-08-28 2000-03-21 Pioneer Hi-Bred International, Inc. Organelle targeting sequences
WO2000023568A2 (en) 1998-10-06 2000-04-27 Albert Einstein College Of Medicine Of Yeshiva University Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells
US6759574B1 (en) 1998-11-05 2004-07-06 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Plants having enhanced gall resistance and methods and compositions for producing same
US20050037335A1 (en) 1998-11-07 2005-02-17 Wolfgang Hillen Method for identifying novel transcriptional regulatory proteins
DE19856052A1 (de) * 1998-12-04 2000-06-08 Deutsches Krebsforsch Konjugat zur Anreicherung in neuronalen Zellen
CA2354195C (en) 1998-12-22 2012-07-17 Dow Agrosciences Llc Methods and genetic compositions to limit outcrossing and undesired gene flow in crop plants
US6903077B1 (en) 1999-01-04 2005-06-07 University Of Vermont And State Agricultural College Methods and products for delivering nucleic acids
DE19900743A1 (de) 1999-01-12 2000-07-13 Aventis Pharma Gmbh Neue komplexbildende Proteine
US6323391B1 (en) 1999-01-25 2001-11-27 Trustees Of The University Of Pennsylvania Methods and transgenic mouse model for identifying and modulating factors leading to motor neuron degeneration
US6849272B1 (en) 1999-04-21 2005-02-01 Massachusetts Institute Of Technology Endosomolytic agents and cell delivery systems
EP1849873B1 (en) 1999-04-29 2011-10-12 Gbp Ip, Llc Method and means for producing high titer, safe, recombinant lentivirus vectors
ES2185595T5 (es) 1999-05-17 2009-12-17 Conjuchem Biotechnologies Inc. Peptidos antivirales modificados y sus composiciones para la prevencion y/o el tratamiento de infecciones viricas.
JP4106402B2 (ja) 1999-05-21 2008-06-25 フジコピアン株式会社 熱転写画像形成方法およびそれに用いる熱転写材の組み合わせ
US7319086B1 (en) 1999-05-28 2008-01-15 University Of Sydney Method of prophylaxis and treatment and agents useful for same
JP4836375B2 (ja) 1999-06-07 2011-12-14 ティーイーティー システムズ ホールディング ゲーエムベーハー ウント ツェーオー． カーゲー 新規の、ｔｅｔリプレッサーに基づく転写調節タンパク質
CA2272788A1 (en) 1999-06-11 2000-12-11 Garching Innovation Gmbh Means and methods for transformation of plant mitochondria
US6770632B1 (en) 1999-07-16 2004-08-03 The General Hospital Corporation Folypolyglutamyl synthetase gene transfer to enhance antifolate
US6586411B1 (en) 2000-08-16 2003-07-01 Mayo Foundation For Medical Education And Research System for monitoring the location of transgenes
US6632800B1 (en) 1999-08-17 2003-10-14 Mayo Foundation For Medical Education And Research System for monitoring the expression of transgenes
US6780639B1 (en) 1999-08-24 2004-08-24 Universite Libre De Bruxelles Antibiotic inducible/repressible genetic construct for gene therapy or gene immunization
HK1046020B (en) 1999-08-25 2007-05-11 Allergan, Inc. Activatable recombinant neurotoxins
US20030104622A1 (en) * 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
US6875448B1 (en) 1999-09-03 2005-04-05 Chugai Seiyaku Kabushiki Kaisha Method of intracellular sustained-release of drug and preparations
US6633933B1 (en) 1999-09-30 2003-10-14 Oak Technology, Inc. Controller for ATAPI mode operation and ATAPI driven universal serial bus mode operation and methods for making the same
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US20040072739A1 (en) 1999-11-10 2004-04-15 Anderson Christen M. Compositions and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetes
US6867036B1 (en) 1999-11-23 2005-03-15 Mayo Foundation For Medical Education And Research Gene expression by positive feedback activation of a cell type-specific promoter
US7060291B1 (en) 1999-11-24 2006-06-13 Transave, Inc. Modular targeted liposomal delivery system
DE10003241A1 (de) 2000-01-26 2001-08-02 Werner Lubitz Verschließen von Bakterienghosts
US6872406B2 (en) 2000-02-11 2005-03-29 Children's Hospital Research Foundation Fusogenic properties of saposin C and related proteins and polypeptides for application to transmembrane drug delivery systems
KR20030000029A (ko) 2000-02-21 2003-01-03 후지사와 야꾸힝 고교 가부시키가이샤 매트릭스 메탈로프로테이나제 저해제로서 티아제피닐하이드록삼산 유도체
KR101215789B1 (ko) 2000-03-30 2012-12-26 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
ATE353361T1 (de) 2000-04-28 2007-02-15 Sangamo Biosciences Inc Gezielten modifikation der chromatinstruktur
US20020151028A1 (en) 2000-05-18 2002-10-17 Cornell Research Foundation, Inc. Structure-based drug design for Ulp1 protease substrates
US7244560B2 (en) 2000-05-21 2007-07-17 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US6544780B1 (en) 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
US20020031818A1 (en) 2000-06-22 2002-03-14 Ronai Ze?Apos;Ev A. Modification of Mdm2 activity
GB0027328D0 (en) 2000-06-23 2000-12-27 Aventis Pharma Inc Bioengineered vehicles for targeted nucleic acid delivery
JP2004519211A (ja) 2000-07-21 2004-07-02 シンジェンタ パーティシペーションズ アーゲー 亜鉛フィンガードメイン認識コードおよびその使用
US6696038B1 (en) 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
GB0027905D0 (en) 2000-11-15 2000-12-27 Glaxo Group Ltd New protein
US7273722B2 (en) 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US6771623B2 (en) 2000-12-01 2004-08-03 Telefonaktiebolaget Lm Ericsson (Publ) Method for ensuring reliable mobile IP service
AU2002238376B2 (en) 2001-01-10 2007-05-10 Lonza Cologne Gmbh Modular transfection systems based on nucleoprotein filaments
US6897196B1 (en) 2001-02-07 2005-05-24 The Regents Of The University Of California pH sensitive lipids based on ortho ester linkers, composition and method
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
GB0106315D0 (en) 2001-03-14 2001-05-02 Ich Productions Ltd Transfection complexes
JP2002368577A (ja) 2001-04-06 2002-12-20 Murata Mfg Co Ltd 二重モードフィルタ
WO2002090495A2 (en) 2001-05-04 2002-11-14 Cornell Research Foundation, Inc. Rapidly cleavable sumo fusion protein expression system for difficult to express proteins
US7741453B2 (en) 2001-05-31 2010-06-22 Conjuchem Biotechnologies, Inc. Long lasting fusion peptide inhibitors for HIV infection
US7314971B2 (en) 2001-07-12 2008-01-01 Basf Plant Science Gmbh Nuclear fertility restorer genes and methods of use in plants
KR100495138B1 (ko) 2001-07-31 2005-06-14 학교법인 한림대학교 식물세포 투과 도메인-화물분자 복합체
DE10143205A1 (de) 2001-09-04 2003-03-20 Icon Genetics Ag Verfahren zur Proteinproduktion in Pflanzen
WO2003025195A2 (en) * 2001-09-17 2003-03-27 Yeda Research And Development Co. Ltd. Nucleic acid constructs for the delivery of polynucleotides into dna-containing organelles,and uses thereof
ATE392216T1 (de) 2001-11-14 2008-05-15 Novavax Inc Mycobakterieller impfstoff
US7750134B2 (en) 2001-11-20 2010-07-06 Sanford-Burnham Medical Research Institute Nucleic acids encoding microbial SUMO protease homologs
US7018819B2 (en) 2001-11-30 2006-03-28 Cellectricon Ab Method and apparatus for manipulation of cells and cell-like structures focused electric fields in microfludic systems and use thereof
WO2003052067A2 (en) 2001-12-13 2003-06-26 University Of Virginia Patent Foundation Vector mediated organelle transfection
US20030186281A1 (en) 2001-12-21 2003-10-02 Wolfgang Hillen Modified tetracycline repressor protein compositions and methods of use
US7220576B2 (en) 2002-01-07 2007-05-22 Lifesensors, Inc. Methods and compositions for protein expression and purification
JP2005514025A (ja) 2002-01-07 2005-05-19 ライフセンサーズ、インク． タンパク質発現及び精製のための方法及び組成
AU2003210422A1 (en) 2002-03-09 2003-09-22 Artemis Pharmaceuticals Gmbh Recombinase fusion protein with enhanced cellular uptake
US7919075B1 (en) 2002-03-20 2011-04-05 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices
EP1495045B1 (en) 2002-03-29 2009-09-02 Creagene, Inc. Cytoplasmic transduction peptides and uses thereof
US20040101874A1 (en) 2002-04-12 2004-05-27 Mitokor Inc. Targets for therapeutic intervention identified in the mitochondrial proteome
AU2003232485A1 (en) 2002-04-18 2003-10-27 Mtm Laboratories Ag Neopeptides and methods useful for detection and treatment of cancer
AU2003234186B2 (en) 2002-04-22 2009-01-22 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of protein kinase C Gamma for pain management
EP1505154B1 (en) 2002-04-30 2015-09-16 Dnavec Research Inc. Paramyxovirus vectors with modified protease-dependent tropism
US6835810B2 (en) 2002-05-13 2004-12-28 Geneshuttle Biopharma, Inc. Fusion protein for use as vector
US7056529B2 (en) 2002-05-14 2006-06-06 University Of Louisville Research Foundation, Inc. Direct cellular energy delivery system
US7273620B1 (en) 2002-05-20 2007-09-25 University Of British Columbia Triggered release of liposomal drugs following mixing of cationic and anionic liposomes
EP1531666B1 (en) 2002-05-29 2013-10-23 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
US7553667B2 (en) 2002-06-06 2009-06-30 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food Regulation of gene expression using chromatin remodelling factors
US7105347B2 (en) 2002-07-30 2006-09-12 Corning Incorporated Method and device for protein delivery into cells
US7371922B2 (en) 2002-07-31 2008-05-13 The Board Of Trustees Of The University Of Illinois Nuclear transfer with porcine embryonic stem cells
US6850133B2 (en) 2002-08-14 2005-02-01 Intel Corporation Electrode configuration in a MEMS switch
DE10238046A1 (de) 2002-08-20 2004-03-04 Giesing, Michael, Prof. Dr.med. Verfahren zum Untersuchen von Körperflüssigkeiten auf Krebszellen, dessen Verwendung, entsprechende Analysekits und Verwendung bestimmter Wirkstoffe zur Behandlung von Krebs
AU2003263199B2 (en) 2002-08-28 2008-05-01 Tet Systems Holding Gmbh & Co., Kg Chromosomal loci for the stringent control of gene activities via transcription activation systems
US7042608B2 (en) 2002-09-18 2006-05-09 Pentax Corporation Scanning optical system
WO2004039029A1 (en) 2002-10-25 2004-05-06 Ut Starcom (China) Co., Ltd. A voice calling handling method using dynamic home agency technology at the whole ip framework
US7459145B2 (en) 2002-10-25 2008-12-02 Georgia Tech Research Corporation Multifunctional magnetic nanoparticle probes for intracellular molecular imaging and monitoring
KR100472938B1 (ko) 2002-10-31 2005-03-11 학교법인 한림대학교 세포침투 효율을 향상시킨 수송도메인-목표단백질-수송도메인 융합단백질 및 그 용도
CN100488491C (zh) 2002-11-21 2009-05-20 派维翁生物技术有限公司 高效融合小泡,其制备方法和含有该小泡的药物组合物
WO2004061077A2 (en) 2002-12-24 2004-07-22 North Carolina State University Increasing gamete production with a gene switch
WO2004061456A2 (de) 2003-01-03 2004-07-22 Alcedo Biotech Gmbh Verwendungen von hmgb, hmgn, hmga proteinen
AU2004204456A1 (en) * 2003-01-09 2004-07-29 Invitrogen Corporation Cellular delivery and activation polypeptide-nucleic acid complexes
US7090837B2 (en) 2003-01-21 2006-08-15 The Salk Institute For Biological Studies Compositions and methods for tissue specific targeting of lentivirus vectors
US7402409B2 (en) 2003-01-23 2008-07-22 Epitomics, Inc. Cell fusion method
US6878374B2 (en) 2003-02-25 2005-04-12 Nitto Denko Corporation Biodegradable polyacetals
US7560264B2 (en) 2003-03-14 2009-07-14 Brookhaven Science Associates, Llc High density growth of T7 expression strains with auto-induction option
US8399217B2 (en) 2003-03-14 2013-03-19 Brookhaven Science Associates, Llc High density growth of T7 expression strains with auto-induction option
CA2523676A1 (en) 2003-05-15 2005-02-17 The Board Of Regents For Oklahoma State University Dna vaccine expressing ha1 of equine-2 influenza virus
GB0313132D0 (en) 2003-06-06 2003-07-09 Ich Productions Ltd Peptide ligands
WO2005003766A2 (en) 2003-06-13 2005-01-13 Whitehead Institute For Biomedical Research Methods of regulating metabolism and mitochondrial function
AU2004316996A1 (en) 2003-06-20 2005-09-15 The Regents Of The University Of California Polypeptide transduction and fusogenic peptides
US20070196334A1 (en) * 2003-06-25 2007-08-23 Shaharyar Khan Modified vectors for organelle transfection
JP2007529191A (ja) 2003-06-26 2007-10-25 ライフセンサーズ、インク． タンパク質発現を増強し、精製する方法及び組成物
WO2005003315A2 (en) * 2003-07-01 2005-01-13 Allele Biotechnology & Pharmaceuticals, Inc. Compositions and methods for peptide-assisted transfection
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
US7048925B2 (en) 2003-08-28 2006-05-23 Nitto Denko Corporation Acid-sensitive polyacetals and methods
JP2005108515A (ja) 2003-09-29 2005-04-21 Sanyo Electric Co Ltd 非水電解質電池
WO2005042560A2 (en) 2003-10-24 2005-05-12 Wake Forest University Health Sciences Non-viral delivery of compounds to mitochondria
US20090208478A1 (en) 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
CA2543257C (en) 2003-10-24 2013-12-31 Gencia Corporation Methods and compositions for delivering polynucleotides
CA2554735A1 (en) 2004-01-30 2005-08-11 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
US7638608B2 (en) 2004-03-17 2009-12-29 Crucell Holland B.V. Assay for the separation and quantification of hemagglutinin antigens
JP4485523B2 (ja) 2004-05-11 2010-06-23 医療法人社団珠光会 腫瘍ワクチンなどへの養子免疫細胞
EP1792181B1 (en) 2004-06-21 2010-11-17 Progenra Inc. Diagnostic and screening methods and kits associated with proteolytic activity
DE602004010112T2 (de) 2004-09-14 2008-09-18 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) In cis regulierte konditionelle Genvektoren
DE602005025676D1 (de) 2004-10-18 2011-02-10 Nitto Denko Corp Intrazelluläre peptidabgabe
US7829104B2 (en) 2004-12-01 2010-11-09 Aeras Global Tb Vaccine Foundation Electroporation of Mycobacterium and overexpression of antigens in mycobacteria
FR2878846B1 (fr) 2004-12-07 2007-02-23 Enscr Composes analogues de lipides membranaires d'archaebacteries et compositions liposomiales integrant de tel composes
US7964571B2 (en) 2004-12-09 2011-06-21 Egen, Inc. Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
US8119369B2 (en) 2004-12-30 2012-02-21 Lifesensors, Inc. Human SUMO-3 for enhancing protein expression
US7741431B2 (en) 2005-02-01 2010-06-22 The United States Of America As Represented By The Secretary Of The Army Liposomes containing novel targeting and/or fusogenic peptides, preparations containing them and therapeutic use thereof
WO2006104615A2 (en) 2005-02-24 2006-10-05 University Of Massachusetts Influenza nucleic acids, polypeptides, and uses thereof
JP2008532549A (ja) 2005-03-15 2008-08-21 アラーガン、インコーポレイテッド 内因性クロストリジウム毒素受容体系に対する増大した標的能力を有する修飾クロストリジウム毒素
EP1861365B1 (en) 2005-03-15 2009-07-01 4Sc Ag N-sulphonylpyrroles and their use as histone deacetylase inhibitors
US7881468B2 (en) 2005-04-08 2011-02-01 Telefonaktiebolaget L M Ericsson (Publ) Secret authentication key setup in mobile IPv6
US8114581B2 (en) 2005-09-15 2012-02-14 The Regents Of The University Of California Methods and compositions for detecting neoplastic cells
ATE512228T1 (de) 2005-11-17 2011-06-15 Tet Systems Gmbh & Co Kg Induzierbare expressionssysteme
ES2325644B1 (es) 2005-12-30 2010-06-28 Universidad Del Pais Vasco (Upv/Ehu) Hexapeptidos no proteolizables inhibidores de la glicoproteina 41 del virus del sida.
US8273867B2 (en) 2006-02-10 2012-09-25 The Regents Of The University Of California Transducible delivery of siRNA by dsRNA binding domain fusions to PTD/CPPS
US7807363B2 (en) 2006-02-28 2010-10-05 Alcon Research, Ltd. Superoxide dismutase-2 expression for glaucoma diagnosis
US7795380B2 (en) 2006-06-02 2010-09-14 University Of Iowa Research Foundation Compositions and methods for nucleic acid delivery
US7993656B2 (en) 2006-07-11 2011-08-09 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
CA2670014A1 (en) 2006-11-22 2008-11-20 Emory University Production of anti-microbial peptides
US7989185B2 (en) 2006-11-29 2011-08-02 The Board Of Trustees Of The Leland Stanford Junior University Rapid, informative diagnostic assay for influenza viruses including H5N1
JPWO2008072781A1 (ja) 2006-12-12 2010-04-02 国立大学法人九州大学 哺乳動物における記憶障害の抑制又は治療方法
TWI328040B (en) 2007-05-04 2010-08-01 Stresspro Biomedicine Inc Expression system of recombinant proteins with enhanced yield and immunogenecity
US7973019B1 (en) 2007-10-03 2011-07-05 Alcon Research, Ltd. Transferrin/transferrin receptor-mediated siRNA delivery
TW200932274A (en) 2007-12-18 2009-08-01 Alcon Res Ltd Interfering RNA delivery system and uses thereof
EP2100961A1 (en) 2008-03-04 2009-09-16 Icon Genetics GmbH Method of protease production in plants
US8103278B2 (en) 2008-04-01 2012-01-24 Mediatek Inc. Method and system for managing idle mode of a mobile node with multiple interfaces
TW200951219A (en) 2008-05-06 2009-12-16 Academia Sinica An improved SUMO fusion protein system for effective production of native proteins
US20090280531A1 (en) 2008-05-06 2009-11-12 Academia Sinica Preparation of Soluble Capsid Proteins of Picornaviruses Using SUMO Fusion Technology
CN101307316B (zh) 2008-07-22 2011-03-16 北京中农颖泰生物技术有限公司 抗菌肽cad在枯草杆菌中的分泌表达及重组枯草杆菌表达系统
US8440449B2 (en) 2008-09-30 2013-05-14 The United States Of America, As Represented By The Secretary Of Agriculture Transformed Saccharomyces cerevisiae engineered for xylose utilization
JP5576382B2 (ja) 2008-10-01 2014-08-20 テット・システムズ・ゲーエムベーハー・ウント・カンパニー・カーゲー テトラサイクリン誘導可能な転写制御配列
US8007786B2 (en) 2009-10-20 2011-08-30 Asi Agenzia Spaziale Italiana Radioprotective SOD soluble isoform and uses thereof
KR20120115976A (ko) 2009-12-07 2012-10-19 시냅틱 리서치, 엘엘씨 프로테아제 활성 저해제의 동정 방법 및 프로테아제 활성의 존재 분석 방법
CA2730618A1 (en) 2010-02-03 2011-08-03 Lifesensors, Inc. Synthetic protease substrates, assay methods using such substrates and kits for practicing the assay

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058488A2 (en) * 1999-03-31 2000-10-05 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides

Also Published As

Publication number Publication date
US8541550B2 (en) 2013-09-24
CA2543257C (en) 2013-12-31
JP2007508846A (ja) 2007-04-12
EP1687017A4 (en) 2009-08-19
EP1687017A2 (en) 2006-08-09
EP2418281A3 (en) 2012-09-19
EP2418281B1 (en) 2016-06-01
ES2411962T3 (es) 2013-07-09
JP2011137001A (ja) 2011-07-14
CA2543257A1 (en) 2005-06-23
EP2418281A2 (en) 2012-02-15
WO2005056752A2 (en) 2005-06-23
US20110300600A1 (en) 2011-12-08
WO2005056752A3 (en) 2005-09-29
WO2005056752A9 (en) 2009-07-23
US20050147993A1 (en) 2005-07-07
AU2004297533A1 (en) 2005-06-23
HK1095738A1 (en) 2007-05-18
EP1687017B1 (en) 2013-03-06
US8039587B2 (en) 2011-10-18
AU2004297533B2 (en) 2010-04-29
AU2010206037A1 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
JP4838722B2 (ja) ポリヌクレオチドを送達する方法、及び送達用組成物
US8507277B2 (en) Nonviral vectors for delivering polynucleotides
US8133733B2 (en) Nonviral vectors for delivering polynucleotides to target tissues
AU2010236076B2 (en) Modified Vectors for Organelle Transfection
US8927691B2 (en) Transducible polypeptides for modifying metabolism
Sebbage Cell-penetrating peptides and their therapeutic applications
US8062891B2 (en) Nonviral vectors for delivering polynucleotides to plants
US11629170B2 (en) Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same
HK1163743A (en) Methods and compositions for delivering polynucleotides
HK1095738B (en) Methods and compositions for delivering polynucleotides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100713

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101006

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110526

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110804

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110913

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110930

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141007

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees